diagnost tool
diagnost tool
price close busi juli
continu like free cash flow-rich safe
larg lab rais pt preview
lh report result tue wed respect continu like
lab lab market expect take share
higher-cost less-effici independ lab hospit lh look
deliv free cash flow respect
pay dividend yield recent news aet open
contract lab de-risk stock lh ep
view inexpens rais pt lh
reiter buy print
seven key call lh quantifi unh/aet contract
beyond guid capit deploy outlook sustain
preview look revenu y/i vs street
adj ep y/i line street look
total volum rev/req growth y/i expect
chang revenue growth guid cfo guid billion
maintain estim though think like upsid revs/
adj ep forecast vs dgx guid
preview lh recalibr pace estim rais
share count share buy-back assumpt tweak lower adj
ep y/i move closer street trim
rev vs street model
dx revenue growth driven growth volum rev/req
respect think could upsid volum estim organ volum
rose reiter rev vs guid
growth adj ep vs guid
aet contract may brought news get access exclus
lh lh get access aet exclus
sinc live bigger aet open contract favor
net share gainer estim add rev first two
year year lh expect lose volum look
gain aet continu drive growth drug develop
busi lh lab rev disclos size
aet contract estim around rev
share shift size assum time lab could captur half larg
contract base estim could bolt net rev lh
time expect volum shift unh/aet take time play beyond
pama look updat acla lawsuit think chang
statu quo lawsuit might propel lh stock higher market
could assign higher multipl draconian reimburs cut
view overhang stock
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
rais pt lh
reiter buy print
price target lh appli multipl unchang adj ep
estim assum view modest earn growth
project believ potenti faster top-lin growth contribut
 accret capit deploy would mark upsid adj ep
price target use multipl unchang adj ep
estim assum view modest earn growth
project believ potenti faster top-lin growth contribut
 accret capit deploy would mark upsid adj ep
diagnost tool
canaccord genuiti estim compani report
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
diagnost tool
canaccord genuiti estim compani report
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin juli et
date time product juli et
price target appli multipl adj ep estim assum view modest
earn growth project believ potenti faster top-lin growth contribut accret capit
deploy would mark upsid adj ep estim
laboratori corpor america hold lh
price target lh appli multipl adj ep estim assum view modest
earn growth project believ potenti faster top-lin growth contribut accret capit
deploy would mark upsid adj ep estim
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
diagnost tool
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
canaccord genuiti one affili compani market maker liquid provid secur laboratori
corpor america hold relat deriv
canaccord genuiti one affili compani intend seek expect receiv compens invest bank
servic laboratori corpor america hold next three month
laboratori corpor america hold rate histori
diagnost tool
rate histori
line articl mifid ii deleg regul disclos price perform preced five year whole period
financi instrument offer invest servic provid less five year pleas note price histori
refer actual past perform past perform reliabl indic futur price and/or perform
